Outset Medical: Profitability Path Brightens
Outset Medical managed notable improvements in operational efficiency and gross margins in Q4.
Outset Medical (NASDAQ:OM), the innovator behind the Tablo Hemodialysis System, reported fourth-quarter earnings on Wednesday, Feb. 19, that topped analysts' consensus expectations on top and bottom lines. Fourth-quarter revenue of $29.5 million exceeded the forecasted $28 million, indicating resilience in revenue growth despite market hurdles. The adjusted EPS loss of $0.37 was better than the projected loss of $0.44.
Overall, the company reported a quarter marked by enhanced operational efficiency and improved financial metrics.
Source: Outset Medical. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.
